SNDX - シンダックス・ファ―マシュ―ティカルズ （Syndax Pharmaceuticals Inc.） シンダックス・ファ―マシュ―ティカルズSNDXのチャート
SNDXの企業情報
| symbol | SNDx |
|---|---|
| 会社名 | Syndax Pharmaceuticals Inc （シンダックス・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 シンダックス・ファーマシューティカルズ（Syndax Pharmaceuticals Inc）は癌の適応症の併用療法のパイプラインを開発することに焦点を当てた臨床段階のバイオ医薬品会社である。製品候補であるエンジノスタット(entinostat)は、フェーズⅡb臨床試験ENCORE 301からの肯定的な結果に続いて、FDAによるブレークスルー療法指定を与えられ、進行ホルモン受容体陽性乳癌の第III相臨床試験で評価される。癌細胞と免疫調節細胞に直接作用するentinostatと、抗CSF-1Rモノクローナル抗体SNDX-6352が、免疫療法に感受性を示す腫瘍に対する身体の免疫応答を増強させている。entinostatは、非小細胞肺癌および黒色腫のためのMerck_Co. Inc.、TNBCのGenentech Inc.および卵巣癌のためのPfizer Inc.およびMerck KGaA Darmstadt Germanyによって、フェーズIb / II臨床試験における併用療法として評価されている。 シンダックス・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。臨床段階で、腫瘍に対する免疫治療の発見・商業化に従事する。経口薬であるエンチノスタットはがん細胞と免疫調整細胞に影響を与え、体の免疫機能を強化させる。肺がん、黒色腫、卵巣がん、乳がんに対する治療に使用される。本社はマサチュ―セッツ州ウォルトハム。 Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin-MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor. |
| 本社所在地 | 35 Gatehouse Drive Building D Floor 3 Waltham MA 02451 USA |
| 代表者氏名 | Dennis G. Podlesak Dennis G. Podlesak |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 781-419-1400 |
| 設立年月日 | 38626 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2016年 |
| 従業員数 | 45人 |
| url | www.syndax.com |
| nasdaq_url | https://www.nasdaq.com/symbol/sndx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -73.41700 |
| 終値（lastsale） | 7.37 |
| 時価総額（marketcap） | 172126445.81 |
| 時価総額 | 時価総額（百万ドル） 170.25800 |
| 売上高 | 売上高（百万ドル） 2.25600 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 70.46800 |
| 当期純利益 | 当期純利益（百万ドル） -71.97700 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Syndax Pharmaceuticals Inc revenues increased 24% to $758K. Net loss increased 42% to $37.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 56% to $29.2M (expense) General and administrative increase of 20% to $7.2M (expense). |
SNDXのテクニカル分析
SNDXのニュース
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 2023/03/06 21:05:00 PR Newswire
WALTHAM, Mass., March 6, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on March 1, 2023 the Company granted an inducement award to purchase up to…
Syndax Pharmaceuticals, Inc. (SNDX) Q4 2022 Earnings Call Transcript 2023/03/03 20:44:05 Seeking Alpha
Syndax Pharmaceuticals, Inc. (NASDAQ:NASDAQ:SNDX) Q4 2022 Results Conference Call February 28, 2023 4:30 PM ETCompany ParticipantsSharon Klahre - Head, Investor RelationsMichael Metzger -…
Syndax Pharmaceuticals: 2023 Is A Pivotal Year 2023/03/01 18:14:51 Seeking Alpha
Syndax has 2 pivotal trials with data readouts in 2023, with possible regulatory filings. Check out why I might be a buyer of SNDX stock at these prices.
Syndax: Q4 Earnings Snapshot 2023/02/28 23:20:20 WTOP
WALTHAM, Mass. (AP) — WALTHAM, Mass. (AP) — Syndax Pharmaceuticals Inc. (SNDX) on Tuesday reported a loss of $39.2 million…
Syndax Pharmaceuticals GAAP EPS of -$0.62 beats by $0.04 2023/02/28 21:50:37 Seeking Alpha
Syndax Pharmaceuticals press release (SNDX): Q4 GAAP EPS of -$0.62 beats by $0.04.As of December 31, 2022, Syndax had cash, cash equivalents, short-term and long-term investments…
Syndax Pharmaceuticals Stock Sees RS Rating Rise To 92 2022/06/30 17:47:00 Investor''s Business Daily
Syndax Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.
Keith Goldan joins Syndax Pharmaceuticals as CFO 2022/06/13 11:37:34 Seeking Alpha
Syndax Pharmaceuticals (SNDX) has appointed Keith Goldan as CFO, effective immediately.Goldan holds nearly 30 years of leadership and operational experience at several…
Syndax Pharmaceuticals Announces Appointment of Keith A. Goldan as Chief Financial Officer 2022/06/13 11:30:00 PR Newswire
WALTHAM, Mass., June 13, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Keith A. Goldan to the role of…
Syndax Pharmaceuticals, Inc. (SNDX) CEO Michael Metzger on Q1 2022 Results - Earnings Call Transcript 2022/05/10 00:13:09 Seeking Alpha
Syndax Pharmaceuticals, Inc. (NASDAQ:NASDAQ:SNDX) Q1 2022 Earnings Conference Call May 09, 2022 04:30 PM ET Company Participants Maghan Meyers - Vice President, Argot Partners Michael…
Syndax Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call Presentation (NASDAQ:SNDX) 2022/05/09 22:56:26 Seeking Alpha
The following slide deck was published by Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc. (SNDX) CEO Michael Metzger on Q1 2022 Results - Earnings Call Transcript 2022/05/10 00:13:09 Seeking Alpha
Syndax Pharmaceuticals, Inc. (NASDAQ:NASDAQ:SNDX) Q1 2022 Earnings Conference Call May 09, 2022 04:30 PM ET Company Participants Maghan Meyers - Vice President, Argot Partners Michael…
Syndax Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call Presentation (NASDAQ:SNDX) 2022/05/09 22:56:26 Seeking Alpha
The following slide deck was published by Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals GAAP EPS of -$0.63 2022/05/09 20:15:23 Seeking Alpha
Syndax Pharmaceuticals press release (SNDX): Q1 GAAP EPS of -$0.63.Total operating expenses of $36.85M.
Syndax Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Business Update 2022/05/09 20:05:00 PR Newswire
– Topline data from revumenib (SNDX-5613) and axatilimab pivotal programs expected starting in 1H23; Company remains on track for two FDA filings in 2023 – – BEAT-AML and AUGMENT-102 trials assessing revumenib (SNDX-5613) in combination with venetoclax-azacitidine for newly diagnosed…